Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Pharmacol Res ; 74: 94-108, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23756200

RESUMEN

We have recently synthesized a new series of 4,5-dihydrobenzo-oxa-cycloheptapyrazole derivatives with the aim to discover novel CB1 antagonist agents characterized by anti-obesity activity comparable to that of SR141716A but with reduced adverse effects such as anxiety and depression. Within the novel class, the CB1 antagonist 8-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4,5-dihydrobenzo-1H-6-oxa-cyclohepta(1,2-c)pyrazole-3-carboxamide (NESS06SM) has been selected as lead compound. We found that NESS06SM is a CB1 neutral antagonist, characterized by poor blood-brain barrier permeability. Moreover, NESS06SM chronic treatment determined both anti-obesity effect and cardiovascular risk factor improvement in C57BL/6N Diet Induced Obesity (DIO) mice fed with fat diet (FD mice). In fact, the mRNA gene expression in Central Nervous System (CNS) and peripheral tissues by real time PCR, showed a significant increase of orexigenic peptides and a decrease of anorexigenic peptides elicited by NESS06SM treatment, compared to control mice fed with the same diet. Moreover, in contrast to SR141716A treatment, the chronic administration of NESS06SM did not change mRNA expression of both monoaminergic transporters and neurotrophins highly related with anxiety and mood disorders. Our results suggest that NESS06SM reduces body weight and it can restore the disrupted expression profile of genes linked to the hunger-satiety circuit without altering monoaminergic transmission probably avoiding SR141716A side effects. Therefore the novel CB1 neutral antagonist could represent a useful candidate agent for the treatment of obesity and its metabolic complications.


Asunto(s)
Fármacos Antiobesidad/uso terapéutico , Benzoxepinas/uso terapéutico , Antagonistas de Receptores de Cannabinoides/uso terapéutico , Obesidad/tratamiento farmacológico , Pirazoles/uso terapéutico , Animales , Fármacos Antiobesidad/farmacología , Benzoxepinas/farmacología , Peso Corporal/efectos de los fármacos , Antagonistas de Receptores de Cannabinoides/farmacología , Dieta Alta en Grasa , Ácido Graso Sintasas/genética , Glucoquinasa/genética , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Obesidad/metabolismo , Piperidinas/farmacología , Piperidinas/uso terapéutico , Pirazoles/farmacología , Piruvato Quinasa/genética , ARN Mensajero/metabolismo , Receptor Cannabinoide CB1/genética , Receptor Cannabinoide CB1/metabolismo , Rimonabant , Simportadores/genética
2.
Behav Pharmacol ; 21(7): 649-53, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20802307

RESUMEN

There is growing evidence to show that atypical antipsychotic quetiapine might exert an anxiolytic effect in patients. Nevertheless, the mechanism underlying this effect has not yet been fully explored. Like other anxiolytic drugs, quetiapine exhibits partial agonistic activity toward serotonergic 1A (5HT1A) receptors. The involvement of the serotonin system in anxiety, particularly of 5HT1A receptors, has been widely documented. In this study we have investigated whether different doses of quetiapine (5, 10, and 30 mg/kg, oral gavage) administered to C57BL6/N mice could produce an anxiolytic effect in the Vogel conflict test, a classical model of anxiety, and whether or not the selective 5HT1A antagonist WAY100635 (0.1 mg/kg, subcutaneously) might prevent such an effect. Our results show that 10 mg/kg quetiapine exhibits an anxiolytic effect, that is, at least in part, 5HT1A-mediated, because it is completely eliminated by WAY100635.


Asunto(s)
Ansiedad/tratamiento farmacológico , Dibenzotiazepinas , Agonistas del Receptor de Serotonina 5-HT1 , Animales , Ansiolíticos/farmacología , Antipsicóticos/farmacología , Ansiedad/fisiopatología , Trastornos de Ansiedad/tratamiento farmacológico , Trastornos de Ansiedad/fisiopatología , Investigación Conductal , Conflicto Psicológico , Dibenzotiazepinas/farmacología , Relación Dosis-Respuesta a Droga , Humanos , Ratones , Ratones Endogámicos C57BL , Modelos Animales , Fumarato de Quetiapina , Ratas , Ratas Wistar , Serotonina/fisiología , Agonistas del Receptor de Serotonina 5-HT1/farmacología , Antagonistas del Receptor de Serotonina 5-HT1/farmacología
3.
Brain Res ; 1048(1-2): 41-7, 2005 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-15913574

RESUMEN

Several converging lines of evidence indicate that drugs of abuse may exert their long-term effects on the central nervous system by modulating signaling pathways controlling gene expression. Cannabinoids produce, beside locomotor effects, cognitive impairment through central CB1 cannabinoid receptors. Data clearly indicate that the cerebellum, an area enriched with CB1 receptors, has a role not only in motor function but also in cognition. This immunohistochemical study examines the effect of delta9-tetrahydrocannabinol (delta9-THC), the principal psychoactive component of marijuana, on the levels of phosphorylated CREB (p-CREB) in the rat cerebellum. Acute treatments with delta9-THC at doses of 5 or 10 mg/kg induced a significant increase of p-CREB in the granule cell layer of the cerebellum, an effect blocked by the CB1 receptor antagonist SR 141716A. Following chronic delta9-THC administration (10 mg/kg/day for 4 weeks), the density of p-CREB was markedly attenuated compared to controls, and this attenuation persisted 3 weeks after withdrawal from delta9-THC. These data provide evidence for the involvement of cerebellar granule cells in the adaptive changes occurring during acute and chronic delta9-THC exposure. This might be a mechanism by which delta9-THC interferes with motor and cognitive functions.


Asunto(s)
Cerebelo/efectos de los fármacos , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Dronabinol/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Psicotrópicos/farmacología , Análisis de Varianza , Animales , Western Blotting/métodos , Recuento de Células , Cerebelo/citología , Relación Dosis-Respuesta a Droga , Dronabinol/antagonistas & inhibidores , Interacciones Farmacológicas , Inmunohistoquímica/métodos , Masculino , Fosforilación/efectos de los fármacos , Piperidinas/farmacología , Pirazoles/farmacología , Ratas , Ratas Sprague-Dawley , Rimonabant , Factores de Tiempo
4.
Psychopharmacology (Berl) ; 172(3): 341-51, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-14634717

RESUMEN

RATIONALE: The anxiolytic effect of ethanol is generally considered to be causally related to the development of alcohol dependence, and serotonin (5-HT) has been involved in both alcohol abuse and anxiety disorders. Several lines of evidence suggest an inverse relationship between alcohol abuse and central serotonergic neurotransmission. OBJECTIVES: When tested in the elevated plus-maze, selectively bred Sardinian alcohol-preferring (sP) rats display a higher degree of anxiety than Sardinian alcohol-non-preferring rats (sNP); this behavior is reversed by voluntary ethanol intake. The present study examined whether sP rats differed with respect to the 5-HT innervation in different forebrain areas. METHODS: We performed an immunohistochemistry study using an antibody raised against serotonin transporter (SERT), a marker for 5-HT fibers, coupled with an unbiased stereology, the method used to count the number of 5-HT neurons in the raphe nuclei. RESULTS: The SERT-positive innervation density was found to be significantly lower in the medial-prefrontal cortex and in the shell of the nucleus accumbens of the ethanol-naive sP rats (sP-N) when compared with the sNP and unselected Wistar rats. No differences were found in the caudate putamen and hippocampus. The stereological analysis showed a significant difference in the number of 5-HT neurons in the dorsal but not in the median raphe of sP-N rats, compared with sNP and Wistar rats. Analysis of the cell body cross-sectional area revealed no differences among the three lines of rats either in the dorsal or in the median raphe. In sP rats that had voluntarily drunk ethanol for 14 consecutive days (sP-exp), no differences were found in the 5-HT innervation relative to sP-N animals. CONCLUSIONS: These results indicate a selective reduction of innervation in the medial portion of the mesocorticolimbic 5-HT system in sP rats, suggesting that this genetically determined difference may be involved in the contrasting alcohol preference and consumption of sP and sNP animals.


Asunto(s)
Alcoholismo/etiología , Ansiedad/complicaciones , Encéfalo/efectos de los fármacos , Proteínas Portadoras/metabolismo , Etanol/farmacología , Glicoproteínas de Membrana/metabolismo , Proteínas de Transporte de Membrana , Proteínas del Tejido Nervioso/metabolismo , Serotonina/metabolismo , Alcoholismo/genética , Alcoholismo/metabolismo , Animales , Encéfalo/metabolismo , Encéfalo/patología , Proteínas Portadoras/efectos de los fármacos , Etanol/administración & dosificación , Inmunohistoquímica , Glicoproteínas de Membrana/efectos de los fármacos , Proteínas del Tejido Nervioso/efectos de los fármacos , Ratas , Ratas Wistar , Proteínas de Transporte de Serotonina en la Membrana Plasmática , Especificidad de la Especie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA